Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats

Hypertension Research

Volumn 30, Issue 12, 2007, Pages 1247-1254

  Sheng, Hongzhuan ^a   Zhu, Jianhua ^a   Wu, Xiaohui ^a   Yang, Di ^b   Zhang, Jinan ^b  

^a NANTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin; Cardiac hypertrophy; Hypertension; Perindopril

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME REPRESSION; GENE EXPRESSION; GRAVIMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HISTOPATHOLOGY; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REMISSION; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WESTERN BLOTTING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CALCINEURIN; CYCLOSPORINE; HEART VENTRICLES; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; MALE; PERINDOPRIL; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 38749107036     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1247     Document Type: Article

References (26)

1. Brown DW, Giles WR, Croft JB: Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848-856.
2. Devereux RB, Roman MJ: Left ventricular hypertrophy in hypertension: stumuli, patterns, and consequences. Hypertens Res 1999; 22: 1-9.
3. Berridge MJ, Bootman MD, Lipp P: Calcium - a life and death signal. Nature 1998; 395: 645-648.
4. Molkentin JD, Lu JR, Antos CL, et al: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 23: 215-228.
5. Koulmann N, Novel-Chate V, Peinnequin A, et al: Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy. Am J Respir Crit Care Med 2006; 174: 699-705.
6. 2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res 2002; 25: 117-124.
7. 2+-dependent calcineurin activation in mechanical stretch-induced hypertrophy. Cardiology 2007; 107: 281-290.
8. Obata K, Nagata K, Iwase M, et al: Overexpression of calmodulin induced cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Biophys Res Commun 2005; 338: 1299-1305.
9. Shikata C, Takeda A, Takeda N: Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy. Mol Cell Biochem 2003; 248: 197-202.
10. Onodera T, Okazaki F, Miyazaki H, et al: Perindopril reverses myocyte remodeling in the hypertensive heart. Hypertens Res 2002; 25: 85-90.
11. Wake R, Kim-Mitsuyama S, Izumi Y, et al: Beneficial effect of candesartan on rat diastolic heart failure. J Pharmacol Sci 2005; 98: 372-379.
12. Hill JA, Karimi M, Kutschke W, et al: Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000; 101: 2863-2869.
13. Diedrichs H, Mei C, Frank KF, et al: Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse rennin gene, TGR (mREN2) 27. J Mol Med 2004; 82: 688-695.
14. Crabtree OF, Olson EN: NFAT signaling: choreographing the social lives of cells. Cell 2002; 109 (Suppl): S67-S79.
15. Ritter O, Hack S, Schuh K, et al: Calcineurin in human heart hypertrophy. Circulation 2002; 105: 2265-2269.
16. Burkard N, Becher J, Heindl C, et al: Targeted proteolysis sustains calcineurin activation. Circulation 2005; 111: 1045-1053.
17. Hallhuber M, Burkard N, Wu R, et al: Inhibition of nuclear import of calcineurin prevents myocardial hypertrophy. Circ Res 2006; 99: 626-635.
18. Lim HW, Windt LJ, Mante J, et al: Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 2000; 32: 697-709.
19. Molkentin JD, Heineke J: Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
20. 2-terminal kinase activation in the heart. J Biol Chem 2000; 275: 13571-13579.
21. Sanna B, Bueno OF, Dai YS, et al: Direct and indirect interaction between calcineruin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 2005; 25: 865-878.
22. Pan F, Sun L, Kardian DB, et al: Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature 2007; 445: 433-436.
23. 2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 2000; 36: 511-516.
24. Nagata K, Somura F, Obata K, et al: AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rat. Hypertension 2002; 40: 168-174.
25. Matsumoto N, Ishimitsu T, Okamura A, et al: Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006; 29: 253-260.
26. Yokoyama H, Averill DB, Brosnihan KB, et al: Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005; 18: 922-929.